Esperion Therapeutics (NASDAQ:ESPR) Insider Sells $37,245.60 in Stock

Esperion Therapeutics, Inc. (NASDAQ:ESPR) insider Benjamin Looker sold 11,824 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total transaction of $37,245.60. Following the sale, the insider owned 667,524 shares of the company’s stock, valued at $2,102,700.60. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $3.15 on Friday. Esperion Therapeutics, Inc. has a 52 week low of $0.95 and a 52 week high of $4.18. The firm has a market capitalization of $811.72 million, a PE ratio of -52.50 and a beta of 1.07. The business’s 50-day simple moving average is $2.78 and its 200-day simple moving average is $3.12.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.08). The business had revenue of $80.10 million for the quarter, compared to the consensus estimate of $84.52 million. Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%.

Wall Street Analyst Weigh In

ESPR has been the subject of several research analyst reports. HC Wainwright cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 target price for the company. in a research note on Friday, May 1st. Citizens Jmp downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Needham & Company LLC lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Piper Sandler cut shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.54.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Wasatch Advisors LP boosted its position in shares of Esperion Therapeutics by 66.9% during the 1st quarter. Wasatch Advisors LP now owns 15,768,897 shares of the biopharmaceutical company’s stock valued at $43,207,000 after acquiring an additional 6,323,138 shares in the last quarter. Orbimed Advisors LLC acquired a new position in Esperion Therapeutics in the fourth quarter worth about $22,072,000. Eversept Partners LP acquired a new position in Esperion Therapeutics in the fourth quarter worth about $14,249,000. Millennium Management LLC lifted its stake in Esperion Therapeutics by 303.4% during the fourth quarter. Millennium Management LLC now owns 3,932,274 shares of the biopharmaceutical company’s stock worth $14,549,000 after purchasing an additional 2,957,418 shares during the period. Finally, Marshall Wace LLP lifted its stake in Esperion Therapeutics by 117.0% during the fourth quarter. Marshall Wace LLP now owns 5,471,611 shares of the biopharmaceutical company’s stock worth $20,245,000 after purchasing an additional 2,950,172 shares during the period. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.